Genetic Tests Identify Risk of Irinotecan-Induced Toxicity: John Logan Black, M.D.

John Logan Black, M.D., explains how Mayo Clinic Laboratories' UGT1A1 tests (Mayo IDs: U1A1Q and UGTFZ) identify genetic variants that increase the risk of potentially life-threatening reactions to irinotecan, a chemotherapy agent.(00:32) Could you give us a brief overview about your background and yourself? (02:16)Could you explain the role of the UGT1A1 gene and its significance in the pharmacogenomics of irinotecan?  (05:34)What specific tests do we offer for UGT1A1 at Mayo Clinic Laboratories? (08:01)Can you clarify the difference between targeted genotyping and full gene sequencing, and when each method is most appropriate? (10:36)Could you elaborate on the specific clinical indications for testing in relation to irinotecan? (13:27)How do UGT1A1 test results impact the dosing of irinotecan? What should clinicians consider when using those results?  (14:02)Are there any other factors or related genes that should be considered alongside UGT1A1, particularly for cancer therapy?